Flowbone

The company develops an injectable bioactive hydrogel platform designed for the targeted prevention of osteoporotic hip fractures. The gel is delivered via a cannula into high-risk bone regions where it initiates the deposition of the body's own minerals to strengthen the bone structure. The technology is intended for the 78 million people worldwide at high risk of hip fractures due to osteoporosis.